Skip to content
Search

Latest Stories

WHO cautions against self-medication with ibuprofen for COVID-19 symptoms

The World Health Organization recommended Tuesday that people suffering from COVID-19-like symptoms should avoid self-medicating with ibuprofen, after French authorities warned anti-inflammatory drugs could worsen the effects of the virus.

The warnings over the weekend by French Health Minister Olivier Veran followed a recent study in The Lancet weekly medical journal that hypothesised that an enzyme that is boosted when taking anti-inflammatory drugs like ibuprofen could facilitate and worsen COVID-19 infections.


Asked about the study, WHO spokesman Christian Lindmeier told reporters in Geneva that the UN health agency's experts were "looking into this to give further guidance."

"In the meantime, we recommend using rather paracetamol, and do not use ibuprofen as a self-medication. That's important," he said.

He stressed though that if ibuprofen had been "prescribed by the healthcare professionals, then, of course, that's up to them."

His comments came after Veran sent a tweet cautioning that the use of ibuprofen and similar anti-inflammatory drugs could be "an aggravating factor" in COVID-19 infections.

"In the case of fever, take paracetamol," he wrote.

He stressed that patients already being treated with anti-inflammatory drugs, should "ask advice from your doctor."

Paracetamol must be taken strictly according to the dose, because too high a dosage can be very dangerous for the liver.

The COVID-19 pandemic, which has infected more than 180,000 people worldwide and killed more than 7,000, causes mild symptoms in most people, but can result in pneumonia and in some cases severe illness that can lead to multiple organ failure.

Even before the pandemic, French authorities last year sounded the alarm over serious "infectious complications" linked to the use of ibuprofen, which is sold under various brands like Nurofen and Advil, and other anti-inflammatory drugs.

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less